What is HC Wainwright’s Forecast for SPTX Q2 Earnings?

Seaport Therapeutics, Inc. (NASDAQ:SPTX) – Equities research analysts at HC Wainwright issued their Q2 2026 EPS estimates for Seaport Therapeutics in a report released on Wednesday, July 15th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.96) per share for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. HC Wainwright also issued estimates for Seaport Therapeutics’ Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($3.25) EPS, Q1 2027 earnings at ($0.61) EPS, Q2 2027 earnings at ($0.64) EPS, Q3 2027 earnings at ($0.66) EPS, Q4 2027 earnings at ($0.69) EPS and FY2027 earnings at ($2.60) EPS.

Seaport Therapeutics (NASDAQ:SPTX) last posted its quarterly earnings data on Monday, June 8th. The company reported ($10.34) earnings per share for the quarter, topping the consensus estimate of ($10.64) by $0.30.

Several other equities analysts have also issued reports on the company. JPMorgan Chase & Co. started coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued an “overweight” rating and a $42.00 price target on the stock. Citigroup started coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $35.00 price objective for the company. Wall Street Zen upgraded shares of Seaport Therapeutics to a “hold” rating in a research report on Saturday, May 9th. UBS Group lowered shares of Seaport Therapeutics to a “sell” rating in a research note on Tuesday, June 9th. Finally, Stifel Nicolaus assumed coverage on shares of Seaport Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $30.00 price target for the company. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Seaport Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $38.40.

Seaport Therapeutics Trading Down 1.4%

Shares of Seaport Therapeutics stock opened at $20.55 on Monday. Seaport Therapeutics has a one year low of $14.85 and a one year high of $23.00. The company’s 50-day simple moving average is $18.54. The company has a market cap of $1.10 billion and a price-to-earnings ratio of -1.99.

Insider Buying and Selling

In other news, major shareholder Arch Venture Partners Xii, Llc acquired 1,100,000 shares of Seaport Therapeutics stock in a transaction on Monday, May 4th. The stock was purchased at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the purchase, the insider owned 6,294,951 shares of the company’s stock, valued at approximately $113,309,118. The trade was a 21.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert J. Hombach acquired 13,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the acquisition, the director owned 13,000 shares of the company’s stock, valued at approximately $235,820. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.